Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 8 of 52 for:    TIMP2

Acute Kidney Injury in Critically Ill Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02765464
Recruitment Status : Recruiting
First Posted : May 6, 2016
Last Update Posted : August 29, 2018
Sponsor:
Information provided by (Responsible Party):
Ronak Raval, Loma Linda University

Brief Summary:
Acute kidney injury (AKI) in critically ill trauma patients has been shown to significantly increase mortality, length of stay, and costs, however detection has proven difficult as markers like elevated creatinine and decreased urine output may take days to manifest and are late indicators of AKI. The combination of two urinary biomarkers, Tissue Inhibitor of Metalloproteinase 2 (TIMP-2) and Insulin-like Growth Factor Binding Protein 7 (IGFBP-7), has been shown to increase within 12 hours following renal insult, allowing assessment of risk for developing acute kidney injury. Therefore, the investigators plan to assess if acute kidney injury in critically ill trauma patients can be determined earlier using urinary TIMP-2 and IGFBP-7 via the NephroCheck testing system. These markers have not been specifically evaluated in trauma patients at risk of AKI.

Condition or disease
Acute Renal Injury

Layout table for study information
Study Type : Observational
Estimated Enrollment : 100 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Predicting Acute Kidney Injury in Critically Ill Trauma Patients Using Metalloproteinase 2 (TIMP2) and Insulin-like Growth Factor Binding Protein7 (IGFBP 7)
Study Start Date : July 2016
Estimated Primary Completion Date : May 2019
Estimated Study Completion Date : May 2019



Primary Outcome Measures :
  1. Measurement of u rinary metalloproteinase 2 (TIMP-2) and Insulin-like growth factor binding protein 7 (IGFBP-7) biomarker elevation that corresponds to acute kidney injury by creatinine and urine output [ Time Frame: one year ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   21 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Subjects must be trauma patients with multiple injuries.
Criteria

Inclusion Criteria:

  • trauma patients with multiple injuries;
  • abdominal injuries;
  • crush injuries;
  • those who present in shock (systolic blood pressure <90 or mean arterial pressure <65);
  • require blood transfusions, vasopressors or mechanical ventilation

Exclusion Criteria:

  • known pregnancy;
  • patients under 21 years of age;
  • known moderate to severe AKI prior to enrollment and end stage renal disease. known moderate to severe AKI prior to enrollment and end stage renal disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02765464


Contacts
Layout table for location contacts
Contact: Patricia Moore, CCRP 909-558-8493 pamoore@llu.edu

Locations
Layout table for location information
United States, California
Loma Linda University Medical Center Recruiting
Loma Linda, California, United States, 92354
Sponsors and Collaborators
Loma Linda University
Investigators
Layout table for investigator information
Principal Investigator: Ronak Raval, MD Loma Linda University Medical Center

Layout table for additonal information
Responsible Party: Ronak Raval, MD, Loma Linda University
ClinicalTrials.gov Identifier: NCT02765464     History of Changes
Other Study ID Numbers: 5160026
First Posted: May 6, 2016    Key Record Dates
Last Update Posted: August 29, 2018
Last Verified: August 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Wounds and Injuries
Critical Illness
Acute Kidney Injury
Disease Attributes
Pathologic Processes
Renal Insufficiency
Kidney Diseases
Urologic Diseases